Amarin Corp Plcuk (AMRN) EBIT Growth (3y) (2013 - 2026)
Amarin Corp Plcuk (AMRN) EBIT Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 7.09% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 12.54% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 51.64% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 19.17% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 8.81% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 9.40% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -102.00% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 39.22% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -37.78% |
| 10 | Amarin Corp Plcuk | 5.86 Bn | 5.54 Bn | 14.99 Mn | 20.56% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 20.56% |
| Mar 31, 2026 | 13.22% |
| Dec 31, 2025 | 12.94% |
| Sep 30, 2025 | -29.23% |
| Jun 30, 2025 | 36.64% |
| Mar 31, 2025 | 16.04% |
| Dec 31, 2024 | -73.86% |
| Sep 30, 2024 | -24.40% |
| Jun 30, 2024 | -27.23% |
| Mar 31, 2024 | -116.91% |
| Dec 31, 2023 | -38.83% |
| Sep 30, 2023 | -45.67% |
| Jun 30, 2023 | -98.02% |
| Mar 31, 2023 | 10.30% |
| Dec 31, 2022 | -55.31% |
| Sep 30, 2022 | -4.42% |
| Jun 30, 2022 | -192.37% |
| Mar 31, 2022 | -7.58% |
| Dec 31, 2021 | 35.86% |
| Sep 30, 2021 | 16.24% |